Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 14/20 | 0.66 |
| ▸ | IKBKE | Q14164 | 13/20 | 0.66 |
| ▸ | AURKA | O14965 | 4/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055195 | 0.90 | AURKA (0.60) | TBK1IKBKEAURKAAURKBCDK2 | |
| SCHEMBL4064138 | 0.88 | TBK1 (0.52) | TBK1IKBKEAURKAAURKBCDK2 | |
| SCHEMBL4053465 | 0.85 | IKBKE (0.49) | TBK1IKBKEAURKAAURKBCDK2 | |
| SCHEMBL4050957 | 0.85 | IKBKE (0.49) | TBK1IKBKEAURKAKDM4ENPC1 | |
| SCHEMBL4059593 | 0.84 | IKBKE (0.47) | TBK1IKBKEAURKAKDM4ENPC1 | |
| SCHEMBL4062911 | 0.83 | IKBKE (0.48) | TBK1IKBKEAURKAKDM4ENPC1 | |
| SCHEMBL4057348 | 0.82 | NOS3 (0.48) | TBK1IKBKEAURKAKDM4EALDH1A1 | |
| SCHEMBL4052372 | 0.82 | AURKA (0.69) | TBK1IKBKEAURKAAURKBCDK2 | |
| SCHEMBL4056063 | 0.82 | PDE5A (0.55) | TBK1IKBKEAURKANPC1RAB9A | |
| SCHEMBL4055769 | 0.81 | NOS1 (0.54) | TBK1IKBKEAURKAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | TBK1 1212/4885IKBKE 129/4885AURKA 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.